CABA ข่าวฟอเร็กซ์

Biotechnology company Cabaletta Bio, Inc. (CABA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of systemic sclerosis (SSc).